Switching to iGlarLixi vs continuation of glucagon-like peptide-1 receptor agonist in inadequately controlled type 2 diabetes: the randomised LixiLan-G trial Article

Web of Science: 000485303803205
Industry Collaboration International Collaboration

Cited authors

  • Blonde, L.; Rosenstock, J.; Del Prato, S.; Henry, R.; Shehadeh, N.; Frias, J.; Niemoeller, E.; Souhami, E.; Wu, J.; Ji, C.; Aroda, V. R.

Authors

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0012-186X

Start page

  • S427

End page

  • S428

Volume

  • 62